CORBUS INTERNATIONAL LIMITED
Company number 11195935 · Monitor this company
Free AI analysis
Have an AI read this company's filings and write an assessment — financial health, risks, and what the numbers say.
Shareholders' funds
£88,389,834
Balance sheet as at 2023-02-28
What it does
The Company is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. The Company's principal activity during the year is the development of its pipeline to prepare for clinical trials, which includes CRB-701, a next generation antibody drug conjugate ("ADC") that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 ("CB1") receptor inverse agonist for the treatment of obesity.
The company's own description, from its latest filed accounts.
Overview
- Company type
- Private Limited Company
- Incorporated
- 2018-02-08
- Employees
- 1 (2023 accounts · was 2 in 2022)
- Registered office
- 5 New Street Square, London, United Kingdom, EC4A 3TW
- Postcode
- EC4A 3TW
- Capital
- 1 GBP
- Accounts category
- Total Exemption Full
Accounts
- Last made up to
- 2025-02-28
- Next due by
- 2026-11-30
- Financial year end
- 28 February
Confirmation statement
- Last statement dated
- 2026-02-07
- Next due by
- 2027-02-21
Nature of business (SIC)
- 82990 Other business support service activities not elsewhere classified
Officers 4 current · 4 resigned
Group structure
Controlled by Corbus Pharmaceuticals, Holdings, Inc. (46434803) — since 2018-02-08
From persons-with-significant-control filings on the public register.
Data protection registration
Registered with the ICO as a data protection fee payer — ZB460220 (Tier 1), registered since 2022.
Information Commissioner's Office register of fee payers, licensed under the Open Government Licence.
Among its peers
Top 1%
by shareholders' funds, of 5,444 similar companies in EC
Trading since 2018.
Competitors London
This company ranks 8 among other business support service activities not elsewhere classified in London.
The class of 2018
23%
of the 28,327 companies in this sector incorporated in 2018 are still active today; 71% have since been dissolved.
A fact about the year, not a forecast for this company.